{"organizations": [], "uuid": "30e041ab1ab17a50ccf001bae9129fdd68d77a0d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180511.html", "section_title": "Archive News &amp; Video for Friday, 11 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-oncolytics-biotech-reports-qtrly-b/brief-oncolytics-biotech-reports-qtrly-basic-and-diluted-loss-per-common-share-of-0-03-idUSASC0A1QX", "country": "US", "domain_rank": 408, "title": "BRIEF-Oncolytics Biotech Reports Qtrly Basic And Diluted Loss Per Common Share Of $0.03", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.154, "site_type": "news", "published": "2018-05-11T19:10:00.000+03:00", "replies_count": 0, "uuid": "30e041ab1ab17a50ccf001bae9129fdd68d77a0d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-oncolytics-biotech-reports-qtrly-b/brief-oncolytics-biotech-reports-qtrly-basic-and-diluted-loss-per-common-share-of-0-03-idUSASC0A1QX", "ord_in_thread": 0, "title": "BRIEF-Oncolytics Biotech Reports Qtrly Basic And Diluted Loss Per Common Share Of $0.03", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "oncolytics biotech inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 11 (Reuters) - Oncolytics Biotech Inc:\n* ONCOLYTICS BIOTECH® REPORTS 2018 FIRST QUARTER RESULTS * ONCOLYTICS BIOTECH INC - QTRLY BASIC AND DILUTED LOSS PER COMMON SHARE $0.03\n* ONCOLYTICS BIOTECH INC - AT MARCH 31, 2018, CO REPORTED $7.7 MILLION IN CASH AND CASH EQUIVALENTS\n* ONCOLYTICS BIOTECH INC - ALL DOLLAR AMOUNTS ARE CANADIAN\n* ONCOLYTICS - ADVANCED PLANS TO RELIST CO’S SHARES ON NASDAQ CAPITAL MARKET EXCHANGE, CONTINUES TO EVALUATE TIMING OF THIS ACTION Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-11T19:10:00.000+03:00", "crawled": "2018-05-12T17:28:28.000+03:00", "highlightTitle": ""}